undamentalytics Newsletter
Sign in

Tango Therapeutics, Inc. income statement

In fiscal 2025, Tango Therapeutics, Inc. reported revenue of $62.4m, up 48.3% on the year before, operating income of −$111m (a -178.4% margin) and net income of −$102m, or −$0.87 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue8372537426254
Research and development5078106115144132134
General and administrative10183036444257
Operating income−52−58−111−114−146−111−136
Net interest income0017869
Income before tax−52−58−108−102−130−102−124
Income tax000000−0
Net income−52−58−108−102−130−102−124
Diluted EPS−$0.81−$0.94−$1.23−$1.08−$1.19−$0.87−$0.92
Diluted shares (average)64m62m88m95m109m116m134m
EBITDA−51−57−109−112−143−109−134

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SIGA vs TNGXGOSS vs TNGXNKTR vs TNGXOCUL vs TNGX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Tango Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tango Therapeutics, Inc.